Bone marrow oedema in sacroiliac joints is common (30-40%) in young athletes and is most frequent in the posterior lower ilium #ACR17 Weber
— Dr. Antoni Chan (@synovialjoints) November 6, 2017
Only 9-14% people with chronic backache see a rheumatologist #ACR17 pic.twitter.com/jq5Y0xFjE6
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
CVD risk in axSpA – Nigil Haroon SPARTAN-GRAPPA-ASAS Symposium #ACR17 pic.twitter.com/BtpXBszcUb
— Marco S Massarotti (@msmassarotti) November 8, 2017
Lots of different causes for Red Eye in autoimmune arthritis. Here’s a list #ACR17 @RheumNow pic.twitter.com/pMi2tLMDpk
— Dr Irwin Lim (@_connectedcare) November 8, 2017
Increased risk of CVA, but not for MI, in AS pts. #ACR17 @RheumNow #2972 https://t.co/5opG0IudgP pic.twitter.com/8PMXbJY7fq
— Dr. Rachel Tate (@uptoTate) November 8, 2017
RheumNow coverage of ACR 2017 mtg is sponsored by Novartis. All content chosen by RheumNow Faculty https://t.co/TuKNHkz089
— Dr. John Cush (@RheumNow) November 8, 2017
#ACR17 Rheumatology Roundup.Cush #11L biologics #2 CA; #1175 biologics infants; #141 Refractory RA; #1885 Epi of AOSD; #200 Gout Telemedicine ; #885 Voclosporin SLE GN. AKavanaugh #271 CD318; #1205 XRT OA? #661 Entheses; #1112 Pred Gout; #541 SIE; #2031 EMR labs; #144 MVA RA
— Dr. John Cush (@RheumNow) November 8, 2017
Continuum of pain from peripheral to central pain states in our rheumatology conditions #ACR17 @RheumNow pic.twitter.com/e03IMwec8o
— Philip Robinson (@philipcrobinson) November 8, 2017
Low mean change in radiographic change after 4 years of Secukinumab treatment in AS, Braun #ACR17 pic.twitter.com/yU4mbtgpvt
— Dr. Antoni Chan (@synovialjoints) November 8, 2017
Dr. Rachel Tate: Adalimumab and Disease Remission
Smoking is associated with higher disease activity and worse quality of life in SpA patients. #ACR17 @RheumNow #2506 https://t.co/eMr1O2K2Ab
— Dr. Rachel Tate (@uptoTate) November 7, 2017
IBD assoc. w/ more severe SpA. Occurs w/ rate of 0.7/100 patient yrs/ 5 yrs in DESIR cohort. #ACR17 @RheumNow #2512 https://t.co/KUA9wC72Ea
— Dr. Rachel Tate (@uptoTate) November 7, 2017
Dr. Julio Gonzalez: Psoriatic Arthritis and AS
RheumNow coverage of ACR 2017 mtg is sponsored by Novartis. All content chosen by RheumNow Faculty https://t.co/1baZR4VaNB
— Dr. John Cush (@RheumNow) November 7, 2017
The all deserved focus on arterial wall inflammation & atherosclerosis in Spa #2545 #2546 #ACR17 @RheumNow pic.twitter.com/dRy9VDTWSX
— Dr. shashank akerkar (@doctorakerkar) November 7, 2017
Don't discount spondyloarthropathy in pts >45yo, esp if pt has psoriasis or inflammatory back pain. #ACR17 @RheumNow #2037 pic.twitter.com/UeAK0kmAPx
— Dr. Paul Sufka (@psufka) November 7, 2017
Low dmard use on AS pts on chronic opioids
#1548#ACR17 @RheumNow pic.twitter.com/7vks8vgV9y— Julio Gonzalez (@japaoli19) November 7, 2017
FUTURE5: Cosentyx clinically&radiofraph superior toPBO. mTSS non-progression 88%Cosentyx vs73% PBO #L17 #acr17 @RheumNow pic.twitter.com/7WI592W3s9
— Olga Petryna (@DrPetryna) November 7, 2017
Dheodar et al-Large study on impact of TNFi on xtra art. comorbidities in AS
#1527#ACR17 @RheumNow pic.twitter.com/xwyUtXkliq— Julio Gonzalez (@japaoli19) November 7, 2017
There were tweets about Landewe’s abstract in SpA…https://t.co/I847KS3cVkhttps://t.co/81ZfAfiBTlhttps://t.co/b4gSqZL7Hm@Drbeckyg
— Chris Wright (@cwrightmd) November 7, 2017
#GAMECHANGER. Ankylosing spondylitis genetics are biased AS parent is more likely to have AS in sons #acr17 @rheumnow #1
— Janet (@Janetbirdope) November 7, 2017
SIJ MRI oedema may be found in many healthy runners @ACRheum #ACR17 pic.twitter.com/l8RtAZvqtJ
— ARD (@ARD_BMJ) November 6, 2017
#1881 #acr17 Uveitis&scleritis common in AI disease. Lack of consensus on workup guidelines calls for Ophtho/rheum collaboration @RheumNow pic.twitter.com/rf1SpRBSrK
— Olga Petryna (@DrPetryna) November 7, 2017
Significant reduction in immunosuppression load on uveitis pts with long term ADA use.#ACR17 @RheumNow
#1115 pic.twitter.com/YM2HM0d9sz— Julio Gonzalez (@japaoli19) November 6, 2017
Developments to watch for- IL-23 important factor in enthesitis #ACR17 pic.twitter.com/jFrpneTUBL
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
#ACR17 Landewe. Stopping adalimumab in nrAxSpA patients in sustained remission leads to flare after 8-12 weeks in 53% pic.twitter.com/n8IY5uzuVF
— Patrick Kiely (@pkiely500) November 6, 2017
How often do you see &Rx non-radiographic axial SpA pts?
— Dr. John Cush (@RheumNow) November 6, 2017
Plenary abst#1787 Landawe presents Atlas 5 study, continuation of ADA is assoc w/ signif less flares in nr-AxSpApts #ACR17 pic.twitter.com/GXgt03aWxT
— Dr. John Cush (@RheumNow) November 6, 2017
Developments in SI joint inflammation scoring in Juvenile SpA #ACR17 @RheumNow pic.twitter.com/ZzydNwZRVT
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
Juvenile SpA: good numbers achieve remission on as well as off meds #ACR17 @RheumNow pic.twitter.com/Abh6Ano7B6
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
Osteitis condensans ilii vs AxSpA.
OCI-no erosions on CT/female sex/hlab27neg/nmlcrp.#ACR17 @RheumNow
#1510 pic.twitter.com/UrcB5g8gyj— Julio Gonzalez (@japaoli19) November 6, 2017
uSpA pts are younger, more likely +HLA-B27, and higher CRP than nrSpA pts. #ACR17 @RheumNow #1506 https://t.co/3z0UDkRiuE pic.twitter.com/2PXhN2AMnK
— Dr. Rachel Tate (@DrRachelTate) November 6, 2017
RheumNow coverage of the ACR 2017 meeting is sponsored by Novartis. All content chosen by RheumNow Faculty https://t.co/HQuFy8vDPj
— Dr. John Cush (@RheumNow) November 6, 2017
AxSpA- Does obesity affect response to TNF blockers? #ACR17 #AnkylosingSpondylitis @RheumNow pic.twitter.com/ubmQHTqdVq
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
Therapies to look forward to in #AnkylosingSpondylitis #ACR17 pic.twitter.com/h9uZQ08wbD
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
The reason why Etoricoxib is preferred NSAID in #AnkylosingSpondylitis #ACR17 @RheumNow pic.twitter.com/gbit47We7n
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
12% progression in 2yrs to AS from nrAxSpA #ACR17 @rheumnow pic.twitter.com/QcFR8zzRXF
— Dr Irwin Lim (@_connectedcare) November 6, 2017
High CRP main predictor of progression of nrAxSpA to AS #ACR17 @RheumNow pic.twitter.com/E84Wfj7B1e
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
Another study discussing progression to AS. Slightly inflammatory last comment #ACR17 @rheumnow pic.twitter.com/UMVZf1rKET
— Dr Irwin Lim (@_connectedcare) November 6, 2017
53% risk of VTE and 62%DVT in AS comparing to general population. Confounders not measured #ACR17 #3S078 @RheumNow pic.twitter.com/h4OnqWwHvt
— Olga Petryna (@DrPetryna) November 5, 2017
Higher risk of VTE on patients hospitalized with SpA, comparable with that of malignancy>OA #879#ACR2017 @RheumNow pic.twitter.com/mOoi8CUUJq
— Julio Gonzalez (@japaoli19) November 5, 2017
#593
EarlyAxSpA DESIR 5 year data
showed low rates of structural progression-SI fatty lesions#ACR17 @RheumNow pic.twitter.com/EFDyzHcIaO— Julio Gonzalez (@japaoli19) November 5, 2017
Higher prevalence of venous thrombosis in SpA admissions- Inflammation driven thrombosis & NSAIDs to blame? Dilli Poudel #879 #ACR17 @RheumNow
— Dr. shashank akerkar (@doctorakerkar) November 5, 2017
Low dose CT detects more spinal progression vs xray in AS measured by ct syndesmophyte sc #582 #ACR17 @rheumnow pic.twitter.com/DfImNVeuIp
— Julio Gonzalez (@japaoli19) November 5, 2017
#578
Of 10 Biomarkers, combo of 2 showed small value added in terms of rad.progression in AxSpA#ACR17 @RheumNow— Julio Gonzalez (@japaoli19) November 5, 2017
Chronic reactive arthritis due to chlamydia could be treated with longterm antibiotics with up to 70% achieving remission #ACR17 pic.twitter.com/eBcaCQEtjm
— Christian Ammitzbøll (@cgytz) November 5, 2017